U. Gatzemeier

21.4k total citations · 7 hit papers
184 papers, 16.3k citations indexed

About

U. Gatzemeier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, U. Gatzemeier has authored 184 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Pulmonary and Respiratory Medicine, 137 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in U. Gatzemeier's work include Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (87 papers) and Cancer therapeutics and mechanisms (43 papers). U. Gatzemeier is often cited by papers focused on Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (87 papers) and Cancer therapeutics and mechanisms (43 papers). U. Gatzemeier collaborates with scholars based in Germany, United States and Italy. U. Gatzemeier's co-authors include Joachim von Pawel, Christian Manegold, E. Kaukel, Paolo Paoletti, Filippo de Marinis, Giorgio V. Scagliotti, Claude Denham, Clet Niyikiza, James T. Symanowski and James J. Rusthoven and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

U. Gatzemeier

180 papers receiving 15.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Frances A. Shepherd, Frank V. Fossella et al. Journal of Clinical Oncology profile →
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2004 1.4k citations Christian Manegold, Giorgio V. Scagliotti et al. Journal of Clinical Oncology profile →
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Joachim von Pawel et al. profile →
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

2007 706 citations U. Gatzemeier, E. Kaukel et al. Journal of Clinical Oncology profile →
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2000 606 citations Claude Denham, Joachim von Pawel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by U. Gatzemeier

Since Specialization

Citations

This map shows the geographic impact of U. Gatzemeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Gatzemeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Gatzemeier more than expected).

Fields of papers citing papers by U. Gatzemeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Gatzemeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Gatzemeier. The network helps show where U. Gatzemeier may publish in the future.

Co-authorship network of co-authors of U. Gatzemeier

This figure shows the co-authorship network connecting the top 25 collaborators of U. Gatzemeier. A scholar is included among the top collaborators of U. Gatzemeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Gatzemeier. U. Gatzemeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma 2023 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Claude Denham, E. Kaukel, Pierre Ruffiè, U. Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti	18
2	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study 2010 ·Lung Cancer ·Martin Reck, Norbert Frickhofen, S. Cedrés, U. Gatzemeier, David F. Heigener, H. G. Fuhr, Aron D. Thall, Silvana Lanzalone, Patricia Stephenson, Ana Ruiz-Garcı́a, Richard C. Chao, Enriqueta Felip	38
3	Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer 2009 ·Annals of Oncology ·E.H. Tan, Janusz Rolski, Tomasz Grodzki, (unknown), U. Gatzemeier, Petr Zatloukal, Enrico Aitini, Giacomo Cartenì, H. Riska, (unknown), Raymond P. Abratt	56
4	XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy 2009 ·Journal of Thoracic Oncology ·U. Gatzemeier, Tudor–Eliade Ciuleanu, Mircea Dediu, (unknown), Heinz Lubenau, Auro del Giglio	63
5	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, (unknown), Anders Mellemgaard, Keunchil Park, (unknown), Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara	2487
6	C6-01: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Giorgio V. Scagliotti, Christopher Kaiser, Bonne Biesma, Christian Manegold, U. Gatzemeier, Piotr Serwatowski, (unknown), Beatrix Bálint, Hans J.M. Smit, Johan Vansteenkiste	9
7	P1-209: Surgery and radiotherapy versus radiotherapy in patients with small-cell lung cancer (SCLC) responding to chemotherapy with paclitaxel, etoposide phosphate, and carboplatin (TEC) - analysis of a randomized phase- II-trial 2007 ·Journal of Thoracic Oncology ·Martin Reck, Michaël Baumann, U. Gatzemeier, Bernward Passlick, Michael Thomas	0
8	P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Patrick Peterson, Keunchil Park, Frank V. Fossella, U. Gatzemeier, William J. John, Giorgio V. Scagliotti	94
9	Gefitinib (‘Iressa’): a new therapy for advanced non-small-cell lung cancer 2005 ·Respiratory Medicine ·Martin Reck, U. Gatzemeier	17
10	Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—A phase II study 2002 ·Lung Cancer ·Martin Reck, (unknown), (unknown), E. Kaukel, (unknown), Joachim von Pawel, (unknown), U. Gatzemeier	8
11	Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial 2002 ·Annals of Oncology ·Rafael Rosell, U. Gatzemeier, Daniel Betticher, U. Keppler, H.-N. Macha, Robert Pirker, Pascaline Berthet, J.L. Breau, P. Lianes, M. Nicholson, Andrea Ardizzoni, A. Chemaissani, Jan Bogaerts, (unknown)	219
12	Lenograstim as Support for ACE Chemotherapy of Small-Cell Lung Cancer 2000 ·American Journal of Clinical Oncology ·U. Gatzemeier, J P Kleisbauer, P. Drings, E. Kaukel, Nikolaos Samaras, (unknown), F. Cardenal, G. Robinet, (unknown), Joachim von Pawel, (unknown)	25
13	Etude multicentrique de phase II de la gemcitabine dans les cancers bronchiques non à petites cellules (CBNPC) 1997 ·Bulletin du Cancer ·Thierry Le Chevalier, Maya Gottfried, U. Gatzemeier, Frances A. Shepherd, P. Weynants, B. Cottier, Harry J.M. Groen, (unknown), K. Mattson, (unknown), Maurizio Tonato, Ronald L. Burkes, Maurizio Voi, (unknown)	1
14	Phase II Clinical Trial of Lobaplatin (D-19466) in Pretreated Patients with Small-Cell Lung Cancer 1996 ·Oncology Research and Treatment ·H.H. Fiebig, H. Henß, (unknown), U. Gatzemeier, C. Manegold, Lutz Edler, Wolfgang E. Berdel	14
15	Lobaplatin (D-19466) in Patients with Advanced Non-Small-Cell Lung Cancer: A Trial of the Association for Medical Oncology (AIO) Phase II Study Group 1996 ·Oncology Research and Treatment ·C. Manegold, P. Drings, U. Gatzemeier, Joachim von Pawel, H.H. Fiebig, W. Queißer, Lutz Edler	7
16	Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy 1993 ·European Journal of Cancer ·V. Trillet-Lenoir, (unknown), C. Manegold, Joachim von Pawel, U. Gatzemeier, B Lebeau, A Depierre, Peter Johnson, Genevieve Decoster, Dianne Tomita, C. Ewen	425
17	Final Evaluation of a Phase II Study on the Effect of Edelfosine (an Ether Lipid) in Advanced Non-Small-Cell Bronchogenic Carcinoma 1992 ·Oncology Research and Treatment ·P. Drings, I Günther, U. Gatzemeier, (unknown), (unknown), W. Schreml, J. Lorenz, W. Brugger, Hans Schick, Joachim von Pawel, Robert J. Nordstrom	17
18	Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. 1992 ·Journal of Clinical Oncology ·U. Gatzemeier, D. K. Hossfeld, (unknown), Martin Reck, W. Achterrath, Luigi Lenaz	12
19	A Randomized Trial with Mitomycin-C/Ifosfamide Versus Mitomycin-C/Vindesine Versus Cisplatin/Etoposide in Advanced Non-Small-Cell Lung Cancer 1991 ·American Journal of Clinical Oncology ·U. Gatzemeier, (unknown), Dieter K. Hossfeld, E. Kaukel, (unknown), (unknown)	15
20	Chemotherapy with Tauromustine in Advanced Non-Small Cell Lung Cancer 1990 ·Oncology Research and Treatment ·U. Gatzemeier, P. Drings, Lutz Edler, Heinz H. Fiebig, Axel Hinke, (unknown), (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact